Immunic market cap
WitrynaContact Email [email protected]. Phone Number +4989208047700. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, … WitrynaImmunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule …
Immunic market cap
Did you know?
Witryna11 godz. temu · The Middle East is the ‘nexus’ of energy and real estate capital markets, says venture capital firm. 02:44. ‘Really elevated’ risk of a U.S. recession at the end of this year, says ... Witryna3 lis 2024 · Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update. News provided by. Immunic, Inc. Nov 03, 2024, 06:30 ET. – $72.8 Million in Cash and Cash Equivalents as ...
Witryna6 kwi 2024 · Immunic, Inc. meldet Ergebnis für das am 31. Dezember 2024 beendete Geschäftsjahr. 22.02. Immunic, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium mit einer Pipeline von selektiven oralen Immunologie-Therapien, die sich auf die Behandlung von chronischen Entzündungs- und … Witryna3 sty 2024 · About Immunic, Inc. 11440 WEST BERNARDO COURT SUITE 300, SAN DIEGO, California, 92127, United States +49 89 2500794 60 https:/www.imux.com. …
WitrynaImmunic (IMUX) - Net assets Net assets on the balance sheet as of December 2024 : $0.11 B. According to Immunic's latest financial reports the company has $0.11 B in … Witryna15 kwi 2024 · Stock split history for Immunic (IMUX) Immunic stock (symbol: IMUX) underwent a total of 1 stock split. The stock split occured on April 15th, 2024. ... The …
WitrynaCurrent and historical revenue charts for Immunic. As of March 2024 Immunic's TTM revenue is of N/A. companies: 7,320 total market cap: $84.507 T. Global ranking; …
WitrynaProvides key financial indicators of Immunic (IMUX), including historical and latest data and analysis. You can query by quarterly, mid-term, and annual reports, and compare historical data easily. iopc findingsWitryna17 lis 2024 · November 17, 2024. NEW YORK, Nov. 17, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the formation of a Scientific-Medical … iopc deathsWitryna31 mar 2024 · Immunic has a market cap or net worth of $66.16 million as of April 1, 2024. Its market cap has decreased by -79.28% in one year. Market Cap 66.16M. … iopc factsWitrynaIMUX: Get the latest Immunic stock price and detailed information including IMUX news, historical charts and realtime prices. ... Market Cap. 44.40 M Number of Shares. 1.30 Day Low. 1.38 ... iopc definition of serious misconductWitryna7 sty 2024 · Vital Therapies and Immunic will host a conference call at 8:00 a.m. ET on January 7, to discuss the proposed transaction. The conference call may be accessed by dialing +1 (855) 765-5682 for U.S ... iop cdcWitryna3 lis 2024 · Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update. PR Newswire. November 3, 2024, 3:30 AM · 16 min read. – $72.8 Million in Cash and Cash Equivalents as ... iopc edwardsvilleWitryna6 kwi 2024 · Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need – Conference Call and Webcast to be Held Today, February 9, 2024, at 11:00 am ET – NEW YORK , Feb. 9, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage … iopc facebook